Endo To Gain Full Control Over Leading Growth Product In Penwest Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
Sale announced concurrently with filing of NDA for new crush-proof formulation of the opioid Opana ER.
You may also be interested in...
Endo Launches Fortesta, Raises 2011 Guidance
Three years after a new management team stepped in at Endo Pharmaceuticals, the specialtypharma appears to be using M&A to diversify successfully beyond its core pain franchise.
Endo Launches Fortesta, Raises 2011 Guidance
Three years after a new management team stepped in at Endo Pharmaceuticals, the specialtypharma appears to be using M&A to diversify successfully beyond its core pain franchise.
Endo Sees Regulatory Setting For Opana ER As "A Moving Target"
CEO says company in discussions about "complete response" letter with FDA and will "work through" FDA's safety-first focus.